AstraZeneca Launches 32 Million Pound Lawsuit Over Fire Safety Defects at Cambridge Research Facility

AstraZeneca has initiated High Court proceedings against International Fire Consultants, seeking £32 million in damages for alleged widespread fire safety defects that reportedly caused significant delays to its £1.1 billion Cambridge headquarters project. The FTSE 100 pharmaceutical company claims the Cheltenham-based fire engineering consultancy, a subsidiary of Netherlands group Kiwa, failed to meet contractual obligations during construction of the Discovery Centre.

The pharmaceutical giant’s ambitious research facility at 1 Francis Crick Avenue represents a substantial investment in British life sciences infrastructure. Originally projected at £330 million with an anticipated completion date of 2016, the project experienced considerable cost escalation before its eventual unveiling in November 2021. The facility accommodates approximately 2,350 research scientists across 16 laboratories and features environmentally conscious design elements, including a distinctive sawtooth roof configuration intended to optimise energy efficiency.

International Fire Consultants received its appointment from Skanska, the site’s initial construction manager, in 2017. According to AstraZeneca’s particulars of claim, the consultancy’s scope of work encompassed extensive fire safety responsibilities. The pharmaceutical company alleges that IFC substantially failed to comply with its duties, leading to widespread defects in fire dampers, smoke dampers, insulation and ductwork following installation.

AstraZeneca’s court filings assert that whilst IFC eventually identified numerous defects, the discovery came unacceptably late in the project timeline. The consultancy reportedly failed to detect issues during either the design stage or initial inspection phase, only identifying problems in 2021 after receiving specific instructions from Mace, which had replaced Skanska as construction manager in 2018, to re-inspect the works after others had flagged potential deficiencies.

The remediation programme, spanning from 2021 to May 2023, allegedly caused critical delays to the Discovery Centre’s completion. AstraZeneca maintains that compliance with contractual obligations would have prevented the installation of defective fire protection systems or enabled substantially earlier remediation without cost to the company. The pharmaceutical group has calculated total costs and losses exceeding £31.7 million.

International Fire Consultants has mounted a robust defence against the claims, arguing that AstraZeneca’s pleaded contractual basis is fundamentally misconceived and incorrect. The consultancy contends that its engagement by Skanska involved a narrower scope than alleged, with broader inspection work undertaken only following subsequent instructions from Mace. IFC has raised limitation period defences, asserting that any potential claims would be subject to the standard six-year limitation period and consequently time-barred.

The defence document suggests that AstraZeneca’s legal action follows the pharmaceutical company’s settlement of final accounts with Skanska, which released the construction firm from liability for latent defects in its works. IFC characterises the claim as misconceived and unfounded in these circumstances.

AstraZeneca has rejected this argument in its court reply, describing IFC’s position as legally incoherent. The company maintains that its final account agreement with Skanska does not alter or affect IFC’s separate liability as a professional consultant engaged to provide fire engineering services.

The project faced additional setbacks during December 2022 when an electrical fault triggered a fire at the facility, causing further delays to full operational status. Despite the complications, the Cambridge site represented a significant endorsement of Britain’s life sciences sector when unveiled. Mace attributed the sharp escalation in project costs to construction complexity, cost inflation exacerbated by sterling depreciation, and increased investment in advanced technologies and equipment.

Both AstraZeneca and International Fire Consultants declined to provide comment on the ongoing litigation. The case highlights the substantial financial and reputational risks associated with major infrastructure projects when disputes arise over professional responsibilities and the adequacy of specialist consultancy services in complex construction environments.